TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...

Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is ...

Shares of TG Therapeutics, Inc. TGTX have rallied 29.5% in the past three months against the industry’s decline of 11.2%. The company’s sole marketed drug Briumvi (ublituximab-xiiy ...

TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the ...

The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing ...

Data from an open-label extension of VISIONARY-MS support an association between gold nanocrystals and neuronal repair and remyelination in patients with stable multiple sclerosis and visual deficits, ...

NEW YORK - TG Therapeutics, Inc. (NASDAQ:TGTX), a biopharmaceutical company with impressive gross profit margins of 88.3% and annual revenue of $329 million, has presented new data on its ...

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple ...

NEW YORK - TG Therapeutics, Inc. (NASDAQ:TGTX), a biopharmaceutical company with impressive gross profit margins of 88.3% and annual revenue of $329 million, has presented new data on its relapsing ...